What is Zacks Research’s Estimate for ALNY Q1 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Analysts at Zacks Research boosted their Q1 2025 EPS estimates for shares of Alnylam Pharmaceuticals in a research report issued on Thursday, March 6th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn ($0.67) per share for the quarter, up from their prior estimate of ($0.94). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.22) EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03).

A number of other research analysts have also recently commented on the stock. Sanford C. Bernstein reduced their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Scotiabank lowered their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research report on Friday, February 14th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Finally, Chardan Capital restated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Trading Down 1.5 %

NASDAQ ALNY opened at $244.52 on Monday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a market capitalization of $31.65 billion, a price-to-earnings ratio of -112.68 and a beta of 0.39. The stock’s 50-day simple moving average is $254.70 and its two-hundred day simple moving average is $261.25. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. The trade was a 10.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,986 shares of company stock worth $20,397,849 in the last three months. 1.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ALNY. Huntington National Bank boosted its stake in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the last quarter. Larson Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the last quarter. Park Square Financial Group LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at $28,000. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $29,000. Finally, R Squared Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $33,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.